A C Ford

Summary

Publications

  1. ncbi Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus
    Alexander C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Leeds, United Kingdom
    Am J Epidemiol 162:454-60. 2005
  2. ncbi Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada
    BMJ 337:a2313. 2008
  3. ncbi Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome
    A C Ford
    Department of Academic Medicine, St James s University Hospital, Leeds, UK
    Aliment Pharmacol Ther 32:144-58. 2010
  4. ncbi Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience
    M B Sprakes
    Leeds Gastroenterology Institute, The Leeds Teaching Hospitals NHS Trust, UK
    Aliment Pharmacol Ther 32:1357-63. 2010
  5. ncbi The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study
    A C Ford
    Leeds Gastroenterology Institute, St James s University Hospital, Leeds, UK
    Aliment Pharmacol Ther 37:323-31. 2013
  6. ncbi Effect of dyspepsia on survival: a longitudinal 10-year follow-up study
    Alexander C Ford
    Leeds Gastroenterology Institute, St James s University Hospital, UK
    Am J Gastroenterol 107:912-21. 2012
  7. ncbi Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, United Kingdom
    Clin Gastroenterol Hepatol 10:513-9. 2012
  8. ncbi Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Am J Gastroenterol 107:167-76; author reply 177. 2012
  9. ncbi 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis
    Alexander C Ford
    Leeds General Infirmary, Leeds Gastroenterology Institute, Leeds, UK
    Am J Gastroenterol 106:413-20. 2011
  10. ncbi What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, Hamilton, Ontario, Canada
    Clin Gastroenterol Hepatol 8:830-7, 837.e1-2. 2010

Detail Information

Publications50

  1. ncbi Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus
    Alexander C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Leeds, United Kingdom
    Am J Epidemiol 162:454-60. 2005
    ..35) and of higher socioeconomic status (adjusted OR=1.58, 95% CI: 1.16, 2.15 (top tertile vs. bottom tertile)). White Caucasian ethnicity, male gender, and higher socioeconomic status are independent risk factors for Barrett's esophagus...
  2. ncbi Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada
    BMJ 337:a2313. 2008
    ..To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome...
  3. ncbi Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome
    A C Ford
    Department of Academic Medicine, St James s University Hospital, Leeds, UK
    Aliment Pharmacol Ther 32:144-58. 2010
    ..Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a significant placebo response...
  4. ncbi Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience
    M B Sprakes
    Leeds Gastroenterology Institute, The Leeds Teaching Hospitals NHS Trust, UK
    Aliment Pharmacol Ther 32:1357-63. 2010
    ..Infliximab is effective for induction and maintenance of remission in patients with Crohn's disease. There are few data, however, examining effect of infliximab therapy on management costs of Crohn's disease...
  5. ncbi The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study
    A C Ford
    Leeds Gastroenterology Institute, St James s University Hospital, Leeds, UK
    Aliment Pharmacol Ther 37:323-31. 2013
    ..Gastro-oesophageal reflux symptoms (GERS) are common in the community. However, few studies have examined their long-term natural history, or impact on survival...
  6. ncbi Effect of dyspepsia on survival: a longitudinal 10-year follow-up study
    Alexander C Ford
    Leeds Gastroenterology Institute, St James s University Hospital, UK
    Am J Gastroenterol 107:912-21. 2012
    ..It is not known, however, whether these conditions affect mortality. We present the results of a large community-based prospective study that examines this issue...
  7. ncbi Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, United Kingdom
    Clin Gastroenterol Hepatol 10:513-9. 2012
    ..However, there has been no meta-analysis of their efficacy in preventing relapse of quiescent UC...
  8. ncbi Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Am J Gastroenterol 107:167-76; author reply 177. 2012
    ..Efficacy of 5-aminosalicylic acids (5-ASAs) in ulcerative colitis (UC) has been studied previously in meta-analyses. However, no recent meta-analysis has studied the relative efficacies of differing routes of administration...
  9. ncbi 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis
    Alexander C Ford
    Leeds General Infirmary, Leeds Gastroenterology Institute, Leeds, UK
    Am J Gastroenterol 106:413-20. 2011
    ..We conducted a systematic review and meta-analysis of RCTs to examine this issue...
  10. ncbi What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, Hamilton, Ontario, Canada
    Clin Gastroenterol Hepatol 8:830-7, 837.e1-2. 2010
    ..However, few studies report the prevalence of endoscopic findings in individuals with dyspepsia. We conducted a systematic review and meta-analysis examining this...
  11. ncbi Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Am J Gastroenterol 106:601-16. 2011
    ..However, several randomized controlled trials (RCTs) have been published recently, and no previous meta-analysis has studied the effect of 5-ASA dosage used...
  12. ncbi Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study
    Alexander C Ford
    Department of Medicine, Division of Gastroenterology, and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Gastroenterology 138:1727-36; quiz e12. 2010
    ..We assessed prevalence of uninvestigated dyspepsia in a cohort of individuals, some of whom were exposed to bacterial dysentery in May 2000, as well as risk factors for dyspepsia in exposed individuals...
  13. ncbi Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome
    Alexander C Ford
    Gastroenterology Division, Health Sciences Center, McMaster University, Hamilton, Ontario, Canada
    Am J Gastroenterol 105:280-8. 2010
    ..Although flawed systematic reviews could compromise optimal decision making, their accuracy has received limited investigation. We assessed conduct of systematic reviews of pharmaceutical interventions for irritable bowel syndrome (IBS)...
  14. ncbi Management of irritable bowel syndrome
    A C Ford
    Department of Academic Medicine, St James s University Hospital, Leeds, UK
    Minerva Gastroenterol Dietol 55:273-87. 2009
    ....
  15. ncbi Epidemiology of Helicobacter pylori infection and public health implications
    Alexander C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Great George Street, Leeds, UK
    Helicobacter 15:1-6. 2010
    ..As yet, no country has adopted public health measures to treat infected individuals or prevent infection in populations at risk...
  16. ncbi Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Room 230, D Floor, Clarendon Wing, Leeds General Infirmary, Great George Street, Leeds LS13EX, UK
    Gut 60:209-18. 2011
    ..There has been no definitive systematic review and meta-analysis to date examining the effect of laxatives and pharmacological therapies in chronic idiopathic constipation (CIC)...
  17. ncbi IBS in 2010: advances in pathophysiology, diagnosis and treatment
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Great George Street, Leeds, UK
    Nat Rev Gastroenterol Hepatol 8:76-8. 2011
    ..2010 saw some key advances across all aspects of IBS, including further advances in our understanding of the pathophysiology, diagnosis and treatment of this condition...
  18. ncbi Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review
    Alexander C Ford
    Leeds Gastroenterology Institute, D Floor, Clarendon Wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    J Gastroenterol 46:421-31. 2011
    ..The causes of irritable bowel syndrome (IBS) remain obscure. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor. We performed a systematic review to examine this issue in detail...
  19. ncbi Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Am J Gastroenterol 106:590-9; quiz 600. 2011
    ..The use of glucocorticosteroids to treat both Crohn's disease (CD) and ulcerative colitis (UC) is widespread, but no systematic review and meta-analysis has examined the issue of efficacy of these agents in its entirety...
  20. ncbi Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Am J Gastroenterol 106:644-59, quiz 660. 2011
    ..Evidence for treatment of the condition with biological therapies exists, but no systematic review and meta-analysis has examined this issue in its entirety...
  21. ncbi Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Am J Gastroenterol 106:617-29. 2011
    ..Evidence for treatment with 5-aminosalicylic acid (5-ASA) drugs is conflicting. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to examine this issue...
  22. ncbi Meta-analysis: the epidemiology of noncardiac chest pain in the community
    A C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
    Aliment Pharmacol Ther 34:172-80. 2011
    ..Prevalence of, and risk factors for, noncardiac chest pain in the community have not been well studied...
  23. ncbi Current guidelines for dyspepsia management
    Alexander C Ford
    Department of Academic Medicine, St James s University Hospital, Leeds, UK
    Dig Dis 26:225-30. 2008
    ..This article compares and contrasts dyspepsia management guidelines from several geographical regions...
  24. ncbi Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care?
    Alexander C Ford
    Department of Academic Medicine, St James s University Hospital, Leeds, United Kingdom
    Pol Arch Med Wewn 119:391-6. 2009
    ....
  25. ncbi Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, Hamilton, Ontario, Canada
    Clin Gastroenterol Hepatol 8:401-9. 2010
    ..Dyspepsia and irritable bowel syndrome (IBS) are common conditions that can coexist in patients. We performed a systematic review and meta-analysis to estimate prevalence of IBS in dyspepsia...
  26. ncbi Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?
    Alexander C Ford
    Gastroenterology Division, McMaster University Medical Centre, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada
    JAMA 300:1793-805. 2008
    ..These individuals are frequently diagnosed with irritable bowel syndrome (IBS) based on their symptoms; however, some may require additional testing or referral to specialists before this diagnosis is made...
  27. ncbi Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis
    A C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, 1200 Main Street West, Hamilton, Ontario, Canada
    Gut 57:1545-53. 2008
    ..Alarm features are used to prioritize access to urgent investigation, but there is little information concerning their utility in the diagnosis of colorectal cancer...
  28. ncbi Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study
    A C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Leeds, UK
    Aliment Pharmacol Ther 28:1013-20. 2008
    ..There are few studies examining the stability of gastrointestinal symptoms during prolonged periods of follow-up...
  29. ncbi Meta-analysis: Helicobacter pylori'test and treat' compared with empirical acid suppression for managing dyspepsia
    A C Ford
    Division of Gastroenterology, McMaster University, Health Sciences Centre, Hamilton, ON, Canada
    Aliment Pharmacol Ther 28:534-44. 2008
    ..Aim To conduct an individual patient data meta-analysis of randomized controlled trials (RCTs) of 'test and treat' vs. empirical acid suppression in adults with uncomplicated dyspepsia in primary care...
  30. ncbi Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use
    A C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Leeds, UK
    Aliment Pharmacol Ther 26:1267-75. 2007
    ..Screening for Helicobacter pylori reduces dyspepsia and dyspepsia-related costs in positive individuals...
  31. ncbi Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study
    Alexander C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Great George Street, Leeds, UK
    Int J Epidemiol 36:1327-33. 2007
    ..pylori) is acquired mainly in childhood, with studies demonstrating this is related to living conditions. Effects of sibling number and birth order on prevalence of infection have not been extensively studied...
  32. ncbi Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study
    Alexander C Ford
    Department of Academic Medicine, Clinical Sciences Building, St James s University Hospital, Leeds, UK
    Gut 56:321-7. 2007
    ..However, few have reported the effect of quality of life on the development of dyspepsia. A 10-year longitudinal follow-up study examining the effect of quality of life on subsequent dyspepsia was performed...
  33. ncbi Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis
    A C Ford
    Gastroenterology Division, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada
    Gut 58:367-78. 2009
    ..Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder. Evidence for treatment of the condition with antidepressants and psychological therapies is conflicting...
  34. ncbi Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada
    Am J Gastroenterol 104:1831-43; quiz 1844. 2009
    ..We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to estimate the efficacy of all available 5-HT agents in IBS...
  35. ncbi Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia
    A C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, Hamilton, ON, Canada
    Aliment Pharmacol Ther 30:28-36. 2009
    ..The prevalence of coeliac disease (CD) may be increased in individuals with dyspepsia, but evidence is conflicting...
  36. ncbi Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis
    Alexander C Ford
    MB MRCP, Gastroenterology Division, McMaster University, Health Sciences Centre, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada
    Arch Intern Med 169:651-8. 2009
    ..Studies suggest that the prevalence of celiac disease is increased in individuals with IBS; however, evidence is conflicting, and current guidelines do not always recommend screening for celiac disease in these individuals...
  37. ncbi Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
    World J Gastroenterol 14:7361-70. 2008
    ..To assess the safety of bismuth used in Helicobacter pylori (H pylori) eradication therapy regimens...
  38. ncbi Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis
    Alexander C Ford
    Gastroenterology Division, McMaster University, Health Sciences Centre, Hamilton, Ontario, Canada
    Clin Gastroenterol Hepatol 7:1279-86. 2009
    ..Small intestinal bacterial overgrowth (SIBO) has been proposed as an etiologic factor in irritable bowel syndrome (IBS), but evidence is conflicting. We conducted a systematic review and meta-analysis of the prevalence of SIBO in IBS...
  39. ncbi Managing dyspepsia
    Alexander C Ford
    Department of Academic Medicine, St James s University Hospital, Leeds, LS9 7TF, UK
    Curr Gastroenterol Rep 11:288-94. 2009
    ..Recent evidence suggests that empirical acid suppression commencing with antacids is as effective as PPI. Screening and treatment of H. pylori in PPI users and the community may reduce the costs of managing dyspepsia...
  40. ncbi Chemoprevention for gastric cancer
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, Great George Street, Leeds, UK
    Best Pract Res Clin Gastroenterol 25:581-92. 2011
    ..There is little convincing evidence that statins have any effect on risk of gastric cancer. More trials on chemoprevention for gastric cancer are therefore urgently required...
  41. ncbi Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, UK
    Am J Gastroenterol 106:2070-7; quiz 2078. 2011
    ..Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue...
  42. ncbi Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience
    N C Suares
    Leeds Gastroenterology Institute, Leeds General Infirmary, UK
    Aliment Pharmacol Ther 35:284-91. 2012
    ....
  43. ncbi Mycophenolate mofetil therapy for refractory inflammatory bowel disease
    S Palaniappan
    Department of Gastroenterology, Leeds General Infirmary, Lees, United Kingdom
    Inflamm Bowel Dis 13:1488-92. 2007
    ..This is an extension of a previously published study from our center with a longer follow-up period and approximately twice the number of patients...
  44. ncbi Systematic review: the effects of fibre in the management of chronic idiopathic constipation
    N C Suares
    Leeds Gastroenterology Institute, Leeds General Infirmary, Great George Street, Leeds, UK
    Aliment Pharmacol Ther 33:895-901. 2011
    ..Patients with chronic idiopathic constipation are often told to increase dietary fibre intake. Whether this is of any benefit remains unclear...
  45. ncbi The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
    P Moayyedi
    Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, HSC 4W8E, Hamilton, ON L8N 3Z5, Canada
    Gut 59:325-32. 2010
    ..Probiotics may benefit irritable bowel syndrome (IBS) symptoms, but randomised controlled trials (RCTs) have been conflicting; therefore a systematic review was conducted...
  46. ncbi Evidence-based management of ulcerative colitis
    D J Gracie
    Leeds Gastroenterology Institute, St James s University Hospital, Leeds, UK
    Minerva Gastroenterol Dietol 58:87-99. 2012
    ..Granulocyte/monocyte adsorptive apheresis could be of benefit in this setting, but most trials have been conducted in the Far East, so the efficacy in Western UC patients is unclear...
  47. ncbi Mycophenolate mofetil in refractory inflammatory bowel disease
    A C Ford
    Centre for Digestive Diseases, Leeds General Infirmary, Leeds, UK; City Hospital NHS Trust, Birmingham, UK
    Aliment Pharmacol Ther 17:1365-9. 2003
    ..Mycophenolate mofetil therapy may have a role for steroid-dependent patients refractory to azathioprine...
  48. ncbi Meta-analysis: Coeliac disease and hypertransaminasaemia
    A Sainsbury
    Leeds Gastroenterology Institute, Leeds General Infirmary, Great George Street, Leeds, UK
    Aliment Pharmacol Ther 34:33-40. 2011
    ..There may be a positive association between coeliac disease and serum hypertransaminasaemia but evidence is conflicting...
  49. ncbi Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis
    S Thanaraj
    Leeds General Infirmary, Leeds Gastroenterology Institute, UK
    Aliment Pharmacol Ther 32:1297-306. 2010
    ..Granulocyte/monocyte adsorptive apheresis (GMAA) may have a role in this situation...
  50. ncbi Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea
    D J Gracie
    Leeds Gastroenterology Institute, St James s University Hospital, Leeds, UK Department of Nuclear Medicine, St James s University Hospital, Leeds, UK Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK
    Neurogastroenterol Motil 24:983-e538. 2012
    ..Almost 40% of those without risk factors had evidence of bile acid malabsorption, and in those meeting criteria for IBS-D prevalence was almost 30%...